Follow
Miquel Duran-Frigola
Miquel Duran-Frigola
Ersilia Open Source Initiative
Verified email at ersilia.io - Homepage
Title
Cited by
Cited by
Year
A reference map of the human binary protein interactome
K Luck, DK Kim, L Lambourne, K Spirohn, BE Begg, W Bian, R Brignall, ...
Nature 580 (7803), 402-408, 2020
9022020
Widespread expansion of protein interaction capabilities by alternative splicing
X Yang, J Coulombe-Huntington, S Kang, GM Sheynkman, T Hao, ...
Cell 164 (4), 805-817, 2016
5442016
Systems analysis of intracellular pH vulnerabilities for cancer therapy
E Persi, M Duran-Frigola, M Damaghi, WR Roush, P Aloy, JL Cleveland, ...
Nature communications 9 (1), 2997, 2018
3372018
Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker
M Duran-Frigola, E Pauls, O Guitart-Pla, M Bertoni, V Alcalde, D Amat, ...
Nature Biotechnology 38 (9), 1087-1096, 2020
113*2020
Isolation of human colon stem cells using surface expression of PTK7
P Jung, C Sommer, FM Barriga, SJ Buczacki, X Hernando-Momblona, ...
Stem Cell Reports 5 (6), 979-987, 2015
672015
Analysis of chemical and biological features yields mechanistic insights into drug side effects
M Duran-Frigola, P Aloy
Chemistry & biology 20 (4), 594-603, 2013
572013
Residues coevolution guides the systematic identification of alternative functional conformations in proteins
P Sfriso, M Duran-Frigola, R Mosca, A Emperador, P Aloy, M Orozco
Structure 24 (1), 116-126, 2016
542016
Recycling side-effects into clinical markers for drug repositioning
M Duran-Frigola, P Aloy
Genome Medicine 4 (1), 1-4, 2012
542012
Drug sensitivity in cancer cell lines is not tissue-specific
S Jaeger, M Duran-Frigola, P Aloy
Molecular cancer 14, 1-4, 2015
512015
Structural systems pharmacology: the role of 3D structures in next-generation drug development
M Duran-Frigola, R Mosca, P Aloy
Chemistry & biology 20 (5), 674-684, 2013
512013
Bioactivity descriptors for uncharacterized chemical compounds
M Bertoni, M Duran-Frigola, P Badia-i-Mompel, E Pauls, M Orozco-Ruiz, ...
Nature Communications 12 (1), 3932, 2021
482021
A community challenge for a pancancer drug mechanism of action inference from perturbational profile data
EF Douglass, RJ Allaway, B Szalai, W Wang, T Tian, A Fernández-Torras, ...
Cell Reports Medicine 3 (1), 2022
392022
Detecting similar binding pockets to enable systems polypharmacology
M Duran-Frigola, L Siragusa, E Ruppin, X Barril, G Cruciani, P Aloy
PLOS Computational Biology 13 (6), e1005522, 2017
392017
Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization
G Moncunill, A Scholzen, M Mpina, A Nhabomba, AB Hounkpatin, ...
Science translational medicine 12 (543), eaay8924, 2020
352020
Connecting chemistry and biology through molecular descriptors
A Fernández-Torras, A Comajuncosa-Creus, M Duran-Frigola, P Aloy
Current Opinion in Chemical Biology 66, 102090, 2022
322022
A chemo-centric view of human health and disease
M Duran-Frigola, D Rossell, P Aloy
Nature communications 5 (1), 5676, 2014
322014
Integrating and formatting biomedical data as pre-calculated knowledge graph embeddings in the Bioteque
A Fernández-Torras, M Duran-Frigola, M Bertoni, M Locatelli, P Aloy
Nature Communications 13 (1), 5304, 2022
312022
IntSide: a web server for the chemical and biological examination of drug side effects
T Juan-Blanco, M Duran-Frigola, P Aloy
Bioinformatics 31 (4), 612-613, 2014
312014
Systems-Wide Prediction of Enzyme Promiscuity Reveals a New Underground Alternative Route for Pyridoxal 5’-Phosphate Production in E. coli
MA Oberhardt, R Zarecki, L Reshef, F Xia, M Duran-Frigola, R Schreiber, ...
PLoS computational biology 12 (1), e1004705, 2016
292016
Dual fluorescence in 9-amino-2, 7, 12, 17-tetraphenylporphycene
M Duran-Frigola, R Tejedor-Estrada, D Sánchez-García, S Nonell
Physical Chemistry Chemical Physics 13 (21), 10326-10332, 2011
292011
The system can't perform the operation now. Try again later.
Articles 1–20